These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 19216452)

  • 1. Use of common seric tumor markers in patients with solid cancers.
    Gara S; Boussen H; Ghanem A; Guemira F
    Tunis Med; 2008 Jun; 86(6):579-83. PubMed ID: 19216452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum tumor markers.
    Perkins GL; Slater ED; Sanders GK; Prichard JG
    Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers for the early detection of cancer: an inflammatory concept.
    Roy HK; Khandekar JD
    Arch Intern Med; 2007 Sep; 167(17):1822-4. PubMed ID: 17893302
    [No Abstract]   [Full Text] [Related]  

  • 4. Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages.
    Wu JT; Erickson AJ; Tsao KC; Wu TL; Sun CF
    Ann Clin Lab Sci; 2000 Apr; 30(2):175-8. PubMed ID: 10807161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Usefulness of CEA, CA 15-3 and CA 125 tumor markers in the differential diagnostics of peritoneal effusion].
    Kiluk MS; Rółkowski R; Zawadzki RJ; Wojtukiewicz MZ
    Pol Merkur Lekarski; 2002 Oct; 13(76):298-301. PubMed ID: 12557435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumour markers in ovarian tumours.
    von Schlippe M; Rustin GJ
    Forum (Genova); 2000; 10(4):383-92. PubMed ID: 11535987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of cardiopulmonary resuscitation on levels of tumour markers.
    Berent R; Auer J; Porodko M; Lamm G; Weber T; Wimmer E; Seier J; Aspöck G; Eber B
    Eur J Cancer Care (Engl); 2006 Jul; 15(3):252-6. PubMed ID: 16882121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Combined use of tumor markers and MRI tomography in differential diagnosis of ovarian neoplasms].
    Pavlov SB; Akulina EA; Pavlova GB
    Klin Med (Mosk); 1999; 77(4):49-51. PubMed ID: 10356919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of bone and tumour markers in patients with malignant diseases.
    Oremek GM; Weis A; Sapoutzis N; Sauer-Eppel H
    Anticancer Res; 2003; 23(2A):987-90. PubMed ID: 12820336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can cancer be diagnosed with a blood test during routine examinations?
    Weiss PA; Weiss PA
    Clin J Oncol Nurs; 2007 Dec; 11(6):940-1. PubMed ID: 18063553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tumor markers in cancer of the digestive system].
    Zinser JW
    Rev Gastroenterol Mex; 1997; 62(3):145-8. PubMed ID: 9480520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solving the overdiagnosis dilemma.
    Esserman L; Thompson I
    J Natl Cancer Inst; 2010 May; 102(9):582-3. PubMed ID: 20413743
    [No Abstract]   [Full Text] [Related]  

  • 13. [Sense and nonsense of tumor markers in practice].
    Joss R; Cerny T
    Schweiz Med Wochenschr; 1990 May; 120(19):693-703. PubMed ID: 1693445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for the clinical use of tumour markers.
    Duffy MJ
    Ann Clin Biochem; 2004 Sep; 41(Pt 5):370-7. PubMed ID: 15333188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tumor markers in gynecological and breast cancer].
    Jobo T; Sato R; Kuramoto H
    Rinsho Byori; 2003 Dec; 51(12):1188-94. PubMed ID: 14743742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total procollagen type 1 amino-terminal propeptide (total P1NP) as a bone metastasis marker in gynecological carcinomas.
    Oremek G; Sauer-Eppel H; Klepzig M
    Anticancer Res; 2007; 27(4A):1961-2. PubMed ID: 17649805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
    Yamamoto K; Imamura H; Matsuyama Y; Hasegawa K; Beck Y; Sugawara Y; Makuuchi M; Kokudo N
    Ann Surg Oncol; 2009 Oct; 16(10):2795-804. PubMed ID: 19669841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical usefulness of tumour markers.
    Lai LC; Cheong SK; Goh KL; Leong CF; Loh CS; Lopez JB; Nawawi H; Sivanesaratnam V; Subramaniam R;
    Malays J Pathol; 2003 Dec; 25(2):83-105. PubMed ID: 16196365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diagnostic significance of tumor markers for gynecologic malignancies].
    Aoki D; Hirasawa A; Susumu N
    Gan To Kagaku Ryoho; 2005 Mar; 32(3):411-6. PubMed ID: 15791829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for prostate cancer in 2007: the PSA era and its challenges are not over.
    Shariat SF; Karakiewicz PI
    Eur Urol; 2008 Mar; 53(3):457-60. PubMed ID: 18079050
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.